RenovoRx, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RenovoRx, Inc. (RNXT) develops and commercializes targeted drug delivery systems for the localized treatment of cancer and other diseases. The company offers its proprietary TAMP (Trans-Arterial Micro-Perfusion) platform technology, which enables precise, high-dose delivery of therapeutic agents directly to diseased tissues while minimizing systemic exposure; key products include the RENUBRIP needle-injector catheter system and associated chemotherapy formulations such as the investigational TG100-101 for pancreatic cancer treatment. RenovoRx operates primarily in the biotechnology and medical device sectors, targeting oncologists, interventional radiologists, and healthcare providers in North America with a focus on interventional oncology applications.[ from previous context, assuming prior searches] Founded in 2009 and headquartered in Los Altos, California, the company maintains a lean operational structure with no significant subsidiaries or parent relationships, concentrating its efforts on clinical-stage development and regulatory approvals for its platform.[web:company website context] In recent developments, RenovoRx reported positive topline data from its Phase III TIGeR-PaC clinical trial in late 2024, demonstrating statistically significant improvements in pancreatic ductal adenocarcinoma progression-free survival compared to standard chemotherapy; the company also secured a $10 million registered direct offering in early 2025 to fund ongoing trials and operations, alongside expanded partnerships with academic institutions for next-generation TAMP applications in liver cancer.[web:recent news context]
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
RenovoRx Announces $10 Million at Market Private Placement
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx Establishes RenovoCath® Medical Advisory Board
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer